Predict your next investment

Venture Capital
nlvpartners.com

See what CB Insights has to offer

Investments

210

Portfolio Exits

51

Funds

9

Service Providers

1

About New Leaf Venture Partners

New Leaf Venture Partners is a leader in healthcare technology venture investing. They focus primarily on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.

New Leaf Venture Partners Headquarter Location

7 Times Square Suite 3502

New York, New York, 10036,

United States

646-871-6400

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing New Leaf Venture Partners

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find New Leaf Venture Partners in 3 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

113 items

S

Synthetic Biology

382 items

C

CB Insights Healthcare Smart Money Investors - 2020

25 items

Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.

Research containing New Leaf Venture Partners

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned New Leaf Venture Partners in 3 CB Insights research briefs, most recently on Feb 16, 2021.

Latest New Leaf Venture Partners News

Electra Therapeutics Announces $84M Series B

Feb 16, 2022

Electra Therapeutics, a clinical stage biotechnology company developing antibody therapies that target signal regulatory proteins (SIRP), announced a $84 million Series B financing co-led by Westlake Village BioPartners and OrbiMed. Other participating investors include Redmile Group, Cormorant Asset Management, Cowen Healthcare Investments, RA Capital, and New Leaf Venture Partners. Electra was previously funded by its parent company, Star Therapeutics. Electra is building a pipeline of novel therapies targeting SIRP, a family of cell surface receptors on various immune cell types. The company is taking a first-in-class approach to engage SIRP beyond the current drug development efforts in cancer, by targeting specific SIRP proteins to deplete targeted pathological immune cells. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.

New Leaf Venture Partners Investments

210 Investments

New Leaf Venture Partners has made 210 investments. Their latest investment was in Cleerly as part of their Series B - II on March 3, 2022.

CBI Logo

New Leaf Venture Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/14/2022

Series B - II

Cleerly

$16.8M

No

1

2/16/2022

Series B

Electra Therapeutics

$84M

Yes

9

2/16/2022

Series A

Star Therapeutics

$100M

Yes

2

12/23/2021

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

12/17/2021

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/14/2022

2/16/2022

2/16/2022

12/23/2021

12/17/2021

Round

Series B - II

Series B

Series A

Series B - II

Series B - II

Company

Cleerly

Electra Therapeutics

Star Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$16.8M

$84M

$100M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

9

2

10

10

New Leaf Venture Partners Portfolio Exits

51 Portfolio Exits

New Leaf Venture Partners has 51 portfolio exits. Their latest portfolio exit was ReViral on April 07, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/7/2022

Acquired

$99M

9

1/26/2022

Acq - Pending

$99M

3

9/15/2021

IPO

$99M

3

9/3/2021

Reverse Merger

Subscribe to see more

Subscribe to see more

10

7/29/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/7/2022

1/26/2022

9/15/2021

9/3/2021

7/29/2021

Exit

Acquired

Acq - Pending

IPO

Reverse Merger

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

9

3

3

10

10

New Leaf Venture Partners Fund History

9 Fund Histories

New Leaf Venture Partners has 9 funds, including New Leaf Ventures III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2015

New Leaf Ventures III

Multi-Stage Venture Capital

Closed

2

6/22/2015

New Leaf Growth Fund I

Subscribe to see more

Subscribe to see more

$99M

10

10/23/2007

New Leaf Ventures II

Subscribe to see more

Subscribe to see more

$99M

10

8/5/2005

New Leaf Ventures I LP

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2000

Sprout Capital IX LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/31/2015

6/22/2015

10/23/2007

8/5/2005

12/31/2000

Fund

New Leaf Ventures III

New Leaf Growth Fund I

New Leaf Ventures II

New Leaf Ventures I LP

Sprout Capital IX LP

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$99M

$99M

$99M

$99M

Sources

2

10

10

10

10

New Leaf Venture Partners Service Providers

1 Service Provider

New Leaf Venture Partners has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

New Leaf Venture Partners Team

13 Team Members

New Leaf Venture Partners has 13 team members, including current Founder, Managing Director, Vijay Lathi.

Name

Work History

Title

Status

Philippe Chambon

Founder

Current

Jeani Delagardelle

Delos Capital, Sprout Group, and Boston Scientific

Founder

Current

Vijay Lathi

Founder, Managing Director

Current

Ian Wilson

Chief Executive Officer

Current

Craig Slutzkin

Chief Financial Officer

Current

Name

Philippe Chambon

Jeani Delagardelle

Vijay Lathi

Ian Wilson

Craig Slutzkin

Work History

Delos Capital, Sprout Group, and Boston Scientific

Title

Founder

Founder

Founder, Managing Director

Chief Executive Officer

Chief Financial Officer

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.